<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04534023</url>
  </required_header>
  <id_info>
    <org_study_id>Ruijinlj</org_study_id>
    <nct_id>NCT04534023</nct_id>
  </id_info>
  <brief_title>A Clinical Study of the Efficacy of Idebenone in the Treatment of iRBD Into Synucleinopathies</brief_title>
  <official_title>A Randomized, Double-blind, Multi-center Clinical Study of the Efficacy of Idebenone in the Treatment of Primary Rapid Eye Movement Sleep Behavior Disorder Into Synucleinopathies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ruijin Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Second Affiliated Hospital of Soochow University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wuhan Union Hospital, China</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ruijin Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      142 cases of patients with iRBD will be recruited from the neurology department of Ruijin&#xD;
      Hospital, th second Affiliated Hospital of Soochow University and wuhan Union Hospital. After&#xD;
      the informed consent was signed, they were divided into a trial group and a control group&#xD;
      randomly. Each group contains 71 cases. The patients in the trial group will be treated with&#xD;
      Idebenone, while the patients in the control group was treated with placebo. Both groups of&#xD;
      subjects will be treated for 5 years, and patients will be followed-up and evaluated in the&#xD;
      first year, 3 years and 5 years after treatment. The observations include the MDS-UPDRS&#xD;
      questionnaires evaluation, blood biomarker measurements and fMRI or PET-MR examination to&#xD;
      make sure whether the patients has converted to synucleinopathies. Study hypothesis:&#xD;
      Idebenone therapy for patients with iRBD is safe and effective in delaying disease&#xD;
      progression into synucleinopathies.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 1, 2020</start_date>
  <completion_date type="Anticipated">September 30, 2026</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2026</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effective</measure>
    <time_frame>5 years</time_frame>
    <description>5-year conversion rate of iRBD patients to synucleinopathies decreased</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ineffective</measure>
    <time_frame>5 years</time_frame>
    <description>5-year conversion rate of iRBD patients to synucleinopathies remained unchanged or increased.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">142</enrollment>
  <condition>Rapid Eye Movement Sleep Behavior Disorder</condition>
  <condition>Synucleinopathy</condition>
  <arm_group>
    <arm_group_label>trial group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Idebenone</intervention_name>
    <description>trial group</description>
    <arm_group_label>trial group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>control group</description>
    <arm_group_label>control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Clinical diagnosed of iRBD.&#xD;
&#xD;
          2. Age between 40 and 75.&#xD;
&#xD;
          3. Be voluntarily to participate in the experiment by signing an informed consent form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Sleep apnea hypopnea syndrome&#xD;
&#xD;
          2. Slow movement, muscle rigidity, tremor or postural instability.&#xD;
&#xD;
          3. Neurological diseases such as cerebral hemorrhage, cerebral infarction, brain trauma,&#xD;
             brain tumor or central nervous system infection.&#xD;
&#xD;
          4. Other sleep disorders or seizures.&#xD;
&#xD;
          5. Alcoholism or drug addiction patients.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jun Liu, Professor</last_name>
    <phone>64370045</phone>
    <phone_ext>+86-021</phone_ext>
    <email>jly0520@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of neurology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200025</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>August 26, 2020</study_first_submitted>
  <study_first_submitted_qc>August 26, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 1, 2020</study_first_posted>
  <last_update_submitted>September 3, 2020</last_update_submitted>
  <last_update_submitted_qc>September 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Synucleinopathies</mesh_term>
    <mesh_term>REM Sleep Behavior Disorder</mesh_term>
    <mesh_term>Mental Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Idebenone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

